Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

CSC Provides Preliminary Update For Q4 And FY12 - Quick Facts

RELATED NEWS
Trade CSC now with 

Computer Sciences Corp. (CSC: Quote) said Tuesday that it expects fourth-quarter GAAP loss to be in the range of $0.92 - $0.96 per share, adjusted net income of about $0.19 - $0.21 per share, revenues of about $4.1 billion and New Business Awards of about $6 billion. Analysts polled by Thomson Reuters expect the company to report earnings of $0.97 per share on revenues of $4.11 billion for the fourth-quarter. Analysts' estimates typically exclude special items.

Looking ahead for fiscal 2012 ended March 30, 2012, the company also expects GAAP loss to be in the range of $27.27 to $27.31 per share, adjusted net income of about $2.45 to $2.49 per share, revenues of about $15.9 billion, and new business awards of $19 billion. Analysts expects the company to report earnings of $4.30 per share on revenues of $16.00 billion for fiscal 2012.

On December 27, 2011, the Company announced a material impairment of its net investment in the UK National Health Service (NHS) contract and at the same time, withdrew its guidance for its fiscal year 2012. Given the uncertainty surrounding the future of the NHS contract, the Company said it was not in a position to reasonably estimate fiscal 2012 financial performance.

On March 5, 2012, the Company announced that it had signed a non-binding letter of intent with the NHS that provided a framework upon which the contract could continue. The parties targeted the completion of a binding interim agreement on or before March 31, 2012.

On April 4, 2012, the Company announced that the parties had not reached a binding agreement and that discussions are continuing.

Register
To receive FREE breaking news email alerts for Computer Sciences Corp. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Swiss drug maker Roche Holding said a late-stage trial of its breast cancer drug Kadcyla did not provide superior results compared with an existing therapy. FCA US, until recently known as Chrysler, said Friday it is recalling 257,000 Dodge Ram pickups. The auto maker says the rear axle pinion nut on certain model year 2005 Dodge Ram 1500 trucks may loosen due to an undersized spline on the pinion gear. If the pinion nut loosens, the rear axle may... This medical device company has a very impressive track record of growing business over the past decade. increasing sales from $490.2 million in 2004 to $1.72 billion this year. The Silicone Hydrogel daily disposable lens portfolio constitutes a major avenue for growth.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.